Pay in 4 interest-free payments of $6.84 Learn more
Ships within 48 hours · Estimated delivery Aug 25 - Aug 30
Reported Adverse Effects In the available case series and observational literature, the most commonly reported adverse effects include: Injection-site redness or mild induration in approximately 8 to 12% of users Transient nausea, most often associated with oral formulations or higher injectable doses Lightheadedness in a small number of patients shortly after injection (under 2% of reported cases) Vivid dreams or mild sleep changes, reported anecdotally by a subset of users with no clear mechanistic explanation No published human case reports as of July 2025 document serious organ toxicity, malignancy, or endocrine disruption attributable to BPC-157
however, it is always advisable to consult your phlebotomist
Verkhivker et al
A qualified healthcare provider can assess whether biomarker data and personal health status support use
This is why Quicksilver's liquid format (held under the tongue before swallowing) achieves superior plasma levels compared to capsule-based liposomal products that rely solely on intestinal absorption
